Abstract:BackgroundThe processes of prostate cancer (PCa) invasion and metastasis are facilitated by proteolytic cascade involving multiple proteases, such as matrix metalloproteinases, serine proteases and cysteine proteases including cathepsin K (CatK). CatK is predominantly secreted by osteoclasts and specifically degrades collagen I leading to bone destruction. PCa and breast cancer preferentially metastasize to the bone. Importantly, CatK expression level is greater in PCa bone metastatic sites compared to primary tumor and normal prostate tissues. However, the underlying mechanism of CatK during PCa metastases into the bone remains to be elucidated. We investigated the functional role of CatK during the PCa establishment and growth process in the murine bone.MethodsCatK mRNA expression was validated by RT-PCR, protein expression by immunoblotting in PCa LNCaP, C4-2B, and PC3 cells as well as in PCa tissues. Its protein production was measured using ELISA assay. The effect of both knockdowns via siRNA and CatK inhibitor was compared in regard to PCa cell invasion. We further studied the dose-dependent CatK inhibitor effect on conditioned media-induced bone resorption. In setting up an animal model, C4-2B cells were injected into the tibiae of SCID mice. The animals treated with either vehicle or CatK inhibitor for 8weeks at the time of tumor cell injection (tumor establishment model; protocol I) or 4weeks after tumor cell injection (tumor progression model; protocol II) were applied to histological and histomorphometric analyses.ResultsWe confirmed CatK expression in PCa LNCaP, C4-2B, and PC3 cells as well as in PCa tissues. Furthermore, we observed the inhibitory effects of a selective CatK inhibitor on PCa cell invasion. The CatK inhibitor dose-dependently inhibited PCa-conditioned media-induced bone resorption. Upon injection of C4-2B cells into the tibiae of SCID mice, the selective CatK inhibitor significantly prevented the tumor establishment in protocol I, and reduced the tumor growth in bone in protocol II. It also decreased serum PSA levels in both animal models. The inhibitory effects of the CatK inhibitor were enhanced in combination with zoledronic acid (ZA).ConclusionThe selective CatK inhibitor may prevent the establishment and progression of PCa in bone, thus making it a novel therapeutic approach for advanced PCa.

Cathepsin K: The Action in and Beyond Bone

Cathepsin K: a therapeutic target for bone diseases.

Advances in Cathepsin K inhibitor Odanacatib in treatment of osteoporosis

Real-time analysis of osteoclast resorption and fusion dynamics in response to bone resorption inhibitors

A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture

Cathepsin K+ Non-Osteoclast Cells in the Skeletal System: Function, Models, Identity, and Therapeutic Implications

Inhibition of cathepsin K promotes osseointegration of titanium implants in ovariectomised rats

Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariae As Potential Candidates for the Treatment of Osteoporosis.

Lead optimization of cathepsin K inhibitors for the treatment of Osteoarthritis

Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption

Targeting Cathepsin K Diminishes Prostate Cancer Establishment and Growth in Murine Bone.

Cathepsin K activity controls cardiotoxin-induced skeletal muscle repair in mice.

Knockout and Double Knockout of Cathepsin K and Mmp9 Reveals a Novel Function of Cathepsin K As a Regulator of Osteoclast Gene Expression and Bone Homeostasis

Discovery of Selective Covalent Cathepsin K Inhibitors Containing Novel 4-Cyanopyrimidine Warhead Based on Quantum Chemical Calculations and Binding Mode Analysis

Integrated machine learning-based virtual screening and biological evaluation for identification of potential inhibitors against cathepsin K

Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers

NVP-BHG712 against postmenopausal osteoporosis in mice by targeting Cathepsin K

Novel selective proline-based peptidomimetics for human cathepsin K inhibition

Increased fracture callus mineralization and strength in cathepsin K knockout mice

Synthesis and Biological Evaluation of Novel Piperidine-3-Carboxamide Derivatives as Anti-Osteoporosis Agents Targeting Cathepsin K

Novel physiological functions of cathepsins B and L on antigen processing and osteoclastic bone resorption